Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults (Q33570118)

28 July 2017

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults (English)

1 reference

28 July 2017

0 references

1 reference

randomized experiment

1 reference

R Carraro

2

0 references

Arne Astrup

object named as

A Astrup

8

0 references

Stephan Rössner

6

object named as

S Rössner

1 reference

28 July 2017

M E J Lean

1

1 reference

28 July 2017

N Finer

3

1 reference

28 July 2017

H Hartvig

4

1 reference

28 July 2017

M L Lindegaard

5

1 reference

28 July 2017

L Van Gaal

7

1 reference

28 July 2017

NN8022-1807 Investigators

9

1 reference

28 July 2017

language of work or name

English

0 references

publication date

14 August 2013

1 reference

International Journal of Obesity

28 July 2017

1 reference

28 July 2017

38

1 reference

28 July 2017

5

1 reference

28 July 2017

689-697

1 reference

https://scigraph.springernature.com/pub.10.1038/ijo.2013.149

28 July 2017

randomized experiment

0 references

exact match

0 references

cites work

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Gastrointestinal issues in the assessment and management of the obese patient

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

GLP-1 and energy balance: an integrated model of short-term and long-term control

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Pooled-data analysis identifies pyloric pressures and plasma cholecystokinin concentrations as major determinants of acute energy intake in healthy, lean men.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Drug treatment of obesity: established and emerging therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Recent advances in obesity pharmacotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Gut hormones as potential new targets for appetite regulation and the treatment of obesity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Cause-specific excess deaths associated with underweight, overweight, and obesity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Overweight, obesity, and blood pressure: the effects of modest weight reduction

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

A role for glucagon-like peptide-1 in the central regulation of feeding

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Prescription of diabetic diets in the 1980s.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials.

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Drug management of obesity--efficacy versus safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Development of a brief measure to assess quality of life in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Variability in the assessment of adverse events in a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

31 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.149

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010971

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23942319

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Geographical variation in adverse event reporting rates in clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23942319

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Obesity and health-related quality of life: a cross-sectional analysis of the US population

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23942319

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/IJO.2013.149

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference